Clifford Stocks
Clifford Stocks is the founder of OncoResponse and currently leads the company. He previously served as Executive Officer and Director at OncoResponse Inc.
OncoResponse raises $150M total, closes $6M Series D in April 2025; backed by ARE, Rice University, Takeda
OncoResponse, headquartered in Seattle, has raised $150M total with a recorded $6M Series D round in April 2025 and is backed by investors including ARE, Rice University, and Takeda Pharmaceuticals.
OncoResponse Raises $27M to Advance Antibody-Based Cancer Immunotherapies OR502 and OR2805
Seattle biotech firm OncoResponse secured $27 million to advance testing of its antibody-based cancer immunotherapy candidates OR502 and OR2805. The funding includes a $13 million grant from the Cancer Prevention and Research Institute of Texas and $14 million from investors led by RiverVest Venture Partners.
OncoResponse raises $40M Series B to advance five antibody-based cancer immunotherapies into preclinical and clinical trials
OncoResponse raised $40 million in a Series B to push five antibody-based cancer immunotherapy candidates into preclinical and clinical studies, bringing total funding to nearly $70 million since its 2015 launch. The company mines antibodies from cancer patients who had exceptional responses to immunotherapy to develop treatments that modulate tumor‑microenvironment immunosuppression.
Organizations
See all 6-
OncoResponse Executive Officer, Director 2017–present, Chief Executive Officer 2015–present · current
-
Theraclone Sciences Chief Executive Officer 2011–2016 · past
-
Calistoga Pharmaceuticals (acquired by Gilead 2011) Chief Business Officer 2009–2011 · past
Education
-
The University of Chicago Booth School of Business MBA, Statistics; Operations; Leadership · 1986–1989
-
University of Utah B.S., Biology · 1976–1980
Online
Questions about Clifford Stocks
Who is Clifford Stocks?
Clifford Stocks is Chief Executive Officer at OncoResponse.
Which organizations is Clifford Stocks associated with?
On Seattle Flow, Clifford Stocks is listed with OncoResponse, Theraclone Sciences, Calistoga Pharmaceuticals (acquired by Gilead 2011) and 3 more.
Where did Clifford Stocks study?
Clifford Stocks studied at The University of Chicago Booth School of Business and University of Utah.
Where is Clifford Stocks based?
Clifford Stocks is based in Seattle, Washington, United States.